Testing whether measurable cancer leftovers predict outcomes
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- You are already enrolled in the CONFIRM phase III trial (NCT03836014)
- You are still on the assigned study treatment about 2 years after randomization (about 21–33 months)
- Your test results show complete response about 2 years after randomization (roughly the same window)
- You can sign informed consent and you’re covered by a social security system (or similar coverage)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
This trial tests a new blood test that looks for tiny amounts of cancer cells left after treatment, using samples from your diagnosis and a simple blood draw. It may help monitor if your remission is lasting.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.